BioSpace News Archive

Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th.

PharmaEssentia USA Corporation announced the recent appointment of three new female executives to the company’s U.S. leadership team.

Venatorx Pharmaceuticals today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.

Revance Therapeutics, Inc. today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for DAXXIFY™ for the treatment of cervical dystonia.

Bausch Health Companies Inc. today announced the presentation of eleven posters during the Fall Clinical Dermatology Conference, which takes place Oct. 20-23, 2022 in Las Vegas, Nev.

Vifor Pharma AG announced that by decision dated October 19, 2022, SIX Exchange Regulation AG has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously.

Alfasigma S.p.A. has completed the acquisition of SOFAR S.p.A., thus officially beginning the integrating process of the two companies.

AlzeCure Pharma announced that an abstract with new preclinical Alzstatin data has been accepted for presentation at the annual Alzheimer conference CTAD, Clinical Trials in Alzheimer’s Disease, which this year is being held in San Francisco on November 29 - December 2.

BrainStorm Cell Therapeutics Inc. announced that a scientific abstract titled ‘NurOwn Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers’ will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, being held from October 26-28th in Amsterdam, NL.

AUM Biosciences Pte. Ltd. and Mountain Crest Acquisition Corp. V announced that they have entered into a definitive business combination agreement.